VKTXW - (Viking Therapeutics Inc.)

 VKTXWのチャート


 VKTXWの企業情報

symbol VKTXW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/vktxw
adr_tso
EBITDA EBITDA ー
終値(lastsale) 13.0749
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 VKTXWのテクニカル分析


 VKTXWのニュース

   Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020  2020/04/23 11:30:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results…
   Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference  2020/04/07 11:30:00 PR Newswire
SAN DIEGO, April 7, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham &…
   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update  2020/02/26 21:15:00 PR Newswire
/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for…
   The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.  2020/02/25 18:19:00 Business Insider
There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants. We identified seven biotechs that have staked their companies — and their stocks — on finding success in NASH in 2020. Those seven are: Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Akero Therapeutics, Viking Therapeutics, Inventiva Pharma, and 89bio 2019 crumbled into a "graveyard of failures" in NASH, as one Wall Street analyst put it. But the small biotech Intercept stood alone in success. Now, the company has to convince regulators to approve its drug, which would be the first-ever NASH treatment. The other six biotechs we highlight have major clinical trial readouts set for 2020, which could prove transformative for these companies in the hunt for additional NASH therapies. Click here for more BI Prime stories . Big drugmakers have faced years of costly failures in the fight to come up with treatments for the silent liver disease known as NASH.
   5 Stocks Analysts Recommend Heading Into 2020  2020/01/01 17:07:33 Benzinga
The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020. Here’s a look at several stocks analysts recommend. Vivint Solar Inc (NYSE: VSLR ) Vivint shares doubled in 2019, but analysts see more upside ahead in the long-term for Vivint. Of the last 10 analysts to publish research on Vivint, nine gave the stock a bullish rating with an average price target of $9.03, suggesting 18% upside. Glu Mobile Inc. (NASDAQ: GLUU ) Investors have few chances to buy stocks at a discount after the market’s big run in 2019, but Gluu shares are down 24% on the year. Gluu reported disappointing numbers and issued lackluster guidance this year, but Wall Street sees the sell-off as a buying opportunity. The 10 most recent research reports on the company resulted in nine bullish ratings with an $8.28 average price target, suggesting 35% upside. Viking Therapeutics Inc (NASDAQ: VKTX ) Viking is a clinical-stage biotech stock developing VK2809, a drug used to treat non-alcoholic steatohepatitis (NASH).
   Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update  2019/11/05 12:00:00 PR Newswire
SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended…
   Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019  2019/10/31 11:30:00 PR Newswire
SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?  2019/05/14 15:06:37 Yahoo Finance
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift…
   Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?  2019/05/09 15:06:17 Yahoo Finance
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than

 関連キーワード  (― 米国株 VKTXW Viking Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)